

Byooviz[™] (ranibizumab-nuna) – New biosimilar launch

- On June 2, 2022, <u>Biogen</u> and <u>Samsung Bioepis announced</u> the launch of <u>Byooviz (ranibizumab-nuna)</u>, a biosimilar to Genentech's <u>Lucentis[®] (ranibizumab)</u>.
 - Byooviz will be commercially available on July 1, 2022.
- The <u>FDA approved</u> Byooviz in September 2021 for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.

— Additional information about Byooviz may be found in a previous Clinical news summary.

- Lucentis is also approved for the treatment of diabetic macular edema and diabetic retinopathy.
- The list price for Byooviz will be \$1,130 per single use vial to administer 0.5 mg via intravitreal injection, which is 40% lower than the current list price of Lucentis.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.